Latest Acetylcholine Stories
-A tiny genetic mutation is the key to understanding why nicotine--which binds to brain receptors with such addictive potency--is virtually powerless in muscle cells that are studded with the same type of receptor.
A research team led by Northwestern University reports that insulin may slow or prevent the damage and memory loss caused by toxic proteins affiliated with Alzheimerâ€™s disease.
Duke University Medical System researchers have discovered there are differing taste pathways for nicotine, which could provide a new approach for future smoking-cessation products.
MADISON, Wis., Jan. 12 /PRNewswire/ -- Mithridion, Inc., a drug development company focusing on serious Central Nervous System disorders, including Alzheimer's disease (AD), announced today that it held an initial closing of $2.9 million in Series B Preferred Stock financing.
Scientists have identified a relationship between two proteins in the brain that has links to both nicotine addiction and autism.
SARASOTA, Fla., Oct. 21 /PRNewswire/ -- A team of world-renowned scientists today announced the launch of Archer Pharmaceuticals, Inc., a new company that will use modern technologies for the identification of novel treatments for Alzheimer's disease.
REYKJAVIK, Iceland, Oct. 3 /PRNewswire-FirstCall/ -- deCODE genetics today announced the filing of an investigational new drug (IND) application for DG071, the company's novel small-molecule modulator of phosphodiesterase 4 (PDE4), with the US Food and Drug Administration (FDA).
U.S. biophysicists say they have clarified the mysterious interaction between cholesterol and the brain's neurotransmitter receptors.
Xel Pharmaceuticals has completed the development of its once-a-week Huperzine A transdermal patch for the treatment of Alzheimer's disease. The prototype transdermal patch can deliver 400800mcg of Huperzine A per day for up to seven days.
Xel Pharmaceuticals, Inc. announced today the completion of the development of its once-a-week Huperzine A transdermal patch for the treatment of Alzheimer's disease (AD). The prototype transdermal patch can deliver 400-800 mcg of Huperzine A per day for up to seven days.
- a meat pie that is usually eaten at Christmas in Quebec